Shannon John Patrick Jr 4

4 · Xeris Biopharma Holdings, Inc. · Filed Feb 2, 2026

AI-generated summary of this filing

Updated Feb 2, 2026

Xeris (XERS) CEO Shannon Patrick Receives RSUs/Options; Shares Withheld

What Happened

Shannon John Patrick Jr., Chief Executive Officer and Director of Xeris Biopharma (XERS), was granted equity on Jan 30, 2026: 478,436 restricted stock units (RSUs) and 639,639 derivative awards (stock options). The grants were recorded at $0 unit price (typical for RSU/option grants).
On Jan 31, 2026, 340,505 shares were surrendered/withheld to satisfy tax and withholding obligations tied to net settlement of vested RSUs. The withheld shares were reported at $7.36 per share, totaling $2,506,117. These withholdings are routine tax-related dispositions, not open-market sales.

Key Details

Transaction dates: Grants recorded 2026-01-30; tax-withholding transfers 2026-01-31. Filing date: 2026-02-02 (Form 4, period of report 2026-01-30).
Grant details: 478,436 RSUs (F1) — vest in equal annual installments over 3 years; 639,639 stock options (derivative, F3) — vest in equal annual installments over 3 years.
Withholding details: 118,134 + 111,621 + 110,750 = 340,505 shares surrendered at $7.36/share to satisfy income tax/withholding (F2); total value ≈ $2,506,117.
Shares owned after the transactions: not specified in the filing.
Filing timeliness: Form lists transactions for late Jan 2026 and was filed Feb 2, 2026; the filing does not indicate a late-report designation.

Context

The RSU awards and option grants are subject to multi-year vesting and do not represent immediate open-market purchases or sales. The withheld shares reflect net settlement/tax withholding on vested RSUs rather than a decision to sell shares on the market.
For retail investors: grants signal long-term compensation alignment but are routine; the withheld shares are administrative and do not necessarily indicate a change in the insider’s market view.

Form 4

Period: 2026-01-30

DirectorSee Remarks

Transactions

Award
Common Stock
[F1]
2026-01-30+478,436→ 3,276,083 total
Tax Payment
Common Stock
[F2]
2026-01-31$7.36/sh−118,134$869,466→ 3,157,949 total
Tax Payment
Common Stock
[F2]
2026-01-31$7.36/sh−111,621$821,531→ 3,046,328 total
Tax Payment
Common Stock
[F2]
2026-01-31$7.36/sh−110,750$815,120→ 2,935,578 total
Award
Stock Option (Right to Buy)
[F3]
2026-01-30+639,639→ 639,639 total
Exercise: $7.36Exp: 2036-01-30→ Common Stock (639,639 underlying)

Footnotes (3)

[F1]These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued employment through such vesting date.
[F2]Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026.
[F3]These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service through such vesting date.

Signature

/s/ Beth Hecht, Attorney-in-Fact|2026-02-02

1 file